Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 396 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Schedule C Clear all
Not listed Not applicable Interventional

Abdominal Closure Bundle to Reduce Surgical Site Infection in Patients Undergoing C-sections. Cesarean Section Lead to Reduction in Surgical Site Infection? - A Randomized Controlled Trial

NCT03500055
View directory record Official record
Conditions
Surgical Site Infection, Cesarean Section; Infection
Interventions
Abdominal Closure Bundle
Procedure
Lead sponsor
Abington Memorial Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Abington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 20, 2026, 11:06 PM EDT
Recruiting Not applicable Interventional

Improving Clinical Efficiency by Reducing Scheduled Follow-ups Using Cochlear America's Population Mean Mapping Strategy

NCT06960616
View directory record Official record
Conditions
Deafness, Cochlear Hearing Loss
Interventions
Changes in traditional follow-up, Population mean mapping
Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Phase 1 Interventional Results available

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

NCT01614197
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
Interventions
Temsirolimus, Etoposide, Cyclophosphamide, Methotrexate, Hydrocortisone, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
25
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 20, 2026, 11:06 PM EDT
Terminated Phase 2 Interventional

Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT00391066
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
FCR + Lumiliximab, FCR
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
53
States / cities
Scottsdale, Arizona • Alhambra, California • Burbank, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Phase 1 Interventional

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

NCT02260661
View directory record Official record
Conditions
Advanced Solid Malignancies, Breast Cancer - ER+, HER2 -, Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Interventions
AZD8835, AZD8835 in combination with fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Denver, Colorado • Greenville, South Carolina • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

NCT02187861
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Venetoclax, Bendamustine, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
17
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

NCT05543616
View directory record Official record
Conditions
SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Interventions
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
6 Months to 11 Years
Enrollment
4,338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Support for Caregivers of Older Adults With Cognitive Decline

NCT04787068
View directory record Official record
Conditions
Caregiver Burden, Depression, Confidence, Self, Cognition, Fatigue, Function
Interventions
Occupational Therapy support
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Not applicable Interventional

Patient Centered Home Exercise Program for Peripheral Artery Disease

NCT02462824
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Home-based exercise intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Not applicable Interventional

Increasing HCV Linkage to Care Among People Who Inject Drugs

NCT04741750
View directory record Official record
Conditions
Hepatitis C
Interventions
Simplified HCV care within a mobile medical unit
Other
Lead sponsor
Family Health Centers of San Diego
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Not applicable Interventional

Improving Adherence to Pharmacological Treatment

NCT00848224
View directory record Official record
Conditions
Medication Adherence
Interventions
systems-based and pharmacist-mediated program
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
30 Years to 85 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Not applicable Interventional Results available

EHR-Based Medication Complete Communication Strategy to Promote Safe Opioid Use

NCT02431793
View directory record Official record
Conditions
Opioid Use, Unspecified
Interventions
EMC2 Strategy, SMS Text Reminders
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 20, 2026, 11:06 PM EDT
Terminated Phase 2 Interventional Results available

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

NCT00276744
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
cetuximab, capecitabine, docetaxel, Erlotinib, Gemcitabine, Irinotecan, mitomycin C, rapamycin, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 20, 2026, 11:06 PM EDT
Active, not recruiting Phase 2 Interventional

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

NCT01709292
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Vemurafenib (All Groups), Vemurafenib (Post Surgery) - Group A + C, Post Surgery - Group B
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 20, 2026, 11:06 PM EDT
Recruiting Phase 2 Interventional

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

NCT05317000
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Combination 5-azacytidine and nivolumab, Nivolumab
Drug
Lead sponsor
Barbara Burtness
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

NCT00515411
View directory record Official record
Conditions
Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
Interventions
Docetaxel, Leucovorin, Fluorouracil, Cisplatin, Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen, Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
15
States / cities
Duarte, California • Pembroke Pines, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enhancing a Sustainable Pharmacy-based Immunization Program in Two States

NCT02615470
View directory record Official record
Conditions
Herpes Zoster, Pneumococcal Infections
Interventions
Enhanced immunization delivery model, Immunization update
Behavioral · Other
Lead sponsor
Auburn University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Auburn, Alabama • Claremont, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

NCT06935266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-881, SC Investigational Needle Sets
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 20, 2026, 11:06 PM EDT
Active, not recruiting Phase 2 Interventional

Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors

NCT03220646
View directory record Official record
Conditions
Brain Tumor
Interventions
abemaciclib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
8
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Phase 1 Interventional

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

NCT03275103
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cevostamab, Tocilizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

NCT00743288
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Panobinostat
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Bakersfield, California • West Hollywood, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

NCT00726323
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
foretinib (formerly GSK1363089 or XL880)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
12
States / cities
Greenbrae, California • San Francisco, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Phase 1 Interventional

A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation

NCT01074203
View directory record Official record
Conditions
Hepatitis C Recurrence
Interventions
Nitazoxanide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 20, 2026, 11:06 PM EDT
Completed Not applicable Interventional Results available

Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett's Esophagus

NCT04301986
View directory record Official record
Conditions
Barrett Esophagus, GERD
Interventions
Cytosponge, Transnasal Endoscopy (TNE), Esophagogastroduodenoscopy
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 20, 2026, 11:06 PM EDT